In the placebo arm, the incidence of migraine attacks (5%) was comparable with previously reported studies with migraine-inducing substances.28 The sample size of the study was calculated beforehand, based on previous studies with PACAP38 and CGRP.53 As with all new results, our data demands confirmation in different cohorts. The gene discussed is ADCYAP1; the disease is migraine disorder.